

AAMP – ADVANCED INTEGRATIVE ONCOLOGY

18 AMA Cat-1 CE / ND: WA & HI Cat-1 (9-Hours of which are Pharmacology)

***CONO & BC ND Credit Applied for**

FRIDAY

7:00 – 8:00

Breakfast

MORNING THEME: Modifying Cancer Risks and the Cancer Stroma

8:00 – 8:15 **Jeremy Phillips** **Welcome & Introductory Remarks**

8:15 – 9:15 **Dr. Anderson** **Cancer Care – It Sure Seems Harder...**

Anyone working with patients who have cancer has experienced some degree of difficulty supporting people with cancer in the past years. And while this increase in aggressive cancer may have many potential causes, the clinician is still faced with the difficult task of helping and managing aggressive disease. This session will discuss potential causes, and potential intervention strategies. A focus on the immunobiology of cancer, the tumor stroma, and cancer stem cells will be paramount.

9:15 – 10:15 **Dr. Marsden** **You can't Grow Daisies in Cement: Strategies for Treating the Stroma**

In this discussion we will review the role of the stroma in cancer development, progression and metastasis. Integrative treatment modalities aimed at treating the tumor microenvironment along with up and coming assessment tools for cancer stroma will be reviewed.

10:15 – 11:00

Break

11:00 – 12:00 **Dr. Smith** **Managing Controllable Risks for Primary and Secondary Prevention – Breast Cancer and Beyond – Part-1**

In this session Dr. Smith will outline the uncontrollable and controllable risks for breast (and other) cancer. Using the knowledge of these factors to implement primary and secondary cancer prevention, Dr. Smith will outline targets the clinician can focus on during the phases of primary and secondary preventive therapies.

12:00 – 12:30 **Medical Presentation – Non-CME**

12:30 – 1:45

Lunch

AFTERNOON THEME: Managing and Mitigating Cancer Risk Factors

1:45 – 2:45 **Dr. Smith** **Managing Controllable Risks for Primary and Secondary Prevention – Breast Cancer and Beyond – Part-2**

In this session Dr. Smith will continue to outline the uncontrollable and controllable risks for breast (and other) cancer. Using the knowledge of these factors to implement primary and secondary cancer prevention, Dr. Smith will outline targets the clinician can focus on during the phases of primary and secondary preventive therapies.

2:45 – 3:15 Dr. Anderson Managing Risk Factors: Cancer and Infectious Diseases – Is the Connection Real (and what do we do about it?)

In this session Dr. Anderson will discuss the published evidence for a cancer – infectious connection and make connections to potential therapies to assist with this particular comorbidity in people with cancer. Connections to immunomodulation, regulation, targeted therapies, and repurposed drugs will be made.

3:15 – 3:45 Medical Presentation – Non-CME

3:45 – 4:30 **Break**

4:30 – 5:15 Dr. Anderson Managing Risk Factors: Diet Targets and Metabolic Flexibility

Diet and cancer care can be a topic fraught with controversy and confusion. In this session Dr. Anderson will discuss the commonality that “metabolic flexibility” brings to patients who are using a spectrum of dietary interventions. A discussion of how metabolic flexibility can fit many diet types, how to assess a patient’s “flexibility”, and common features of therapeutic dietary interventions regardless of diet type.

5:15 – 6:00 **Clinical Panel – Primary and Secondary Cancer Preventive Strategies**

6:00 – 7:30 **Evening Reception**

SATURDAY

7:00 – 8:00 **Breakfast**

MORNING THEME: Cancer Assessment Options

8:00 – 9:00 Dr. Anderson Oncology Patient Assessment Basics: Testing Strategies

In this session Dr. Anderson will discuss entry level testing strategies to assess and follow disease in the patient with cancer. Tests that are predictive and part of typical standard testing make the base of cancer monitoring. These tests will be discussed and evaluated as to their actual usefulness, ability to incorporate into treatment plans, and predictive value. This discussion will set up the following discussions of precision cancer assessment.

9:00 – 9:45 Dr. Marsden Precision Oncology Assessments and Integrative Treatments – Part-1

Overview of the current state of science for precision oncology within the context of screening, surveillance and targeted treatment guidance. Particular emphasis on the use of genomic variation assessments to guide targeted integrative therapies.

9:45 – 10:30 **Break**

10:30 – 11:15 Dr. Marsden Precision Oncology Assessments and Integrative Treatments – Part-2

Overview of the current state of science for precision oncology within the context of screening, surveillance and targeted treatment guidance. Particular emphasis on the use of genomic variation assessments to guide targeted integrative therapies.

11:15 – 11:30 Dr.’s Marsden and Anderson Moderated Morning Session Q&A

11:30 – 12:00 Medical Presentation – Non-CME

12:00 – 1:15 **Lunch**

AFTERNOON THEME: Managing Cancer and New Directions

1:15 – 2:00 Dr. Smith Managing Cancer Treatment Side Effects

In this session Dr. Smith will outline strategies for dealing with common cancer treatment related side effects. Assessing, predicting, and intervening to aid patient quality of life will be the focus of this talk.

2:00 – 3:00 Dr. Anderson Autologous Immunotherapies – What, Why, How?

Dendritic cell therapies? NK cell enrichment? Tumor Infiltrating Lymphocytes (TILs)? LAK cells? We may have heard of these therapies, or may be incorporating these therapies. They seem to make a lot of clinical sense but can also be mysterious and confusing. In this session Dr. Anderson will break down the types of therapies, technical requirements to achieve them, and potential uses in cancer therapy. This session will also create a base for the following targeted therapies sessions.

3:00 – 3:30 Medical Presentation – Non-CME

3:30 – 4:15 **Break**

4:15 – 5:15 Dr. Goodyear Paradigm Change in Integrative Oncology – New Directions

Where can integrative and cutting-edge cancer therapy possibly go? Cancer is a difficult and evasive disease and requires constant innovation. In this session Dr. Goodyear will describe the next levels of integrative cancer care, how they play out in clinical cases, and where they are headed. Discussion of multiomics, precision cancer therapies, and the change in paradigm from “systemic → tumor” to “tumor → systemic” therapeutic targeting.

5:15 – 6:00 **Clinical Panel – Precision Therapeutics and Next Steps**

6:00 – 7:30 **Evening Demonstration, Hors d'oeuvres & Interactive Workshops**

SUNDAY

7:30 – 8:30 **Breakfast**

MORNING THEME: Advanced Integrative Oncology-1

8:30 – 9:30 Dr. Marsden Advanced Applications in Mistletoe therapy

Dr. Marsden is considered a leading expert in mistletoe therapies and has years of clinical experience behind his expertise. This session will review the advanced use of mistletoe in cancer care including intravenous, intravesicular and intralesional application.

9:30 – 10:30 Dr. Anderson: Oncology Therapy Updates – Hydrogen, FMT, and beyond...

“Repurposed Drugs” in oncology are popular and show some promise. What categories do the most? How do they primarily work? How can one implement them safely in a cancer patient’s case? These and other critical questions will be addressed in this session.

10:30 – 11:15

Break

11:15 – 12:15 Dr. Goodyear Next Level Intratumoral Therapies: Part-1

As an extension of his prior session Dr. Goodyear will elaborate on the clinical applications of targeted therapies using their scientific basis as well as relating clinical cases to describe their real world uses. The promise of these therapies, their pitfalls, and supportive therapies needed after their implementation will be discussed.

12:15 – 1:15

Lunch

AFTERNOON THEME: Advanced Integrative Oncology-2

1:15 – 1:45 Dr. Goodyear Next Level Intratumoral Therapies: Part-2

Dr. Goodyear will finish the discussion of primary intratumoral targeted therapies using case examples and clinical pearls. This session will end with a Q&A session related to this topic.

1:45 – 2:45 Dr. Goodyear Targeted Therapies in Managing Remission

Once a patient reaches “NED” or remission, how can targeted therapies play a role in maintaining that remission? A look at the use of targeted therapies and also the supportive therapies needed when the patient returns home will be explained using patient flow examples and case studies.

2:45 – 3:00

Brief Comfort Break

3:00 – 4:00 Dr. Anderson Repurposed Medications in Oncology – Critical Updates

How can antiparasitic, antibiotic, antifungal, autonomic, cholesterol, and other drugs potentially help in cancer care? Why would they even work? In this session Dr. Anderson will relate experience from twenty years of experience in the use of “repurposed” oncology drugs. Where do they fit in therapeutic order? How can we optimize them? When should they be implemented? And more.

4:00 – 4:30 **Clinical Panel – Targeted Therapies and Patient Management**

4:30

Closing Remarks & Adjourn